Skip to main content
. 2020 Jul 14;6(2):e001282. doi: 10.1136/rmdopen-2020-001282

Table 1.

Baseline characteristics of 9004 RA patients identified in the Swedish Rheumatology Quality Register (SRQ), 2006–2016*

Overall AITD+† AITD−†
Characteristics (n=9 004) (n=1 003) (n=8 001)
Sex
 Women 6072 (67.4) 886 (88.3) 5186 (64.8)
 Men 2932 (32.6) 117 (11.7) 2815 (35.2)
Age at inclusion in SRQ/index date‡ 65.8 (15.0) 68.3 (14.1) 65.5 (15.1)
RA diagnosis§
 Seropositive RA 6088 (67.6) 694 (69.2) 5394 (67.4)
 Seronegative RA 2687 (29.8) 272 (27.1) 2415 (30.2)
 Unspecified RA 229 (2.5) 37 (3.7) 192 (2.4)
Duration of symptoms (months) 5.5 (3.3) 5.5 (3.3) 5.5 (3.3)
Year of inclusion in SRQ
 2006 690 (7.7) 68 (6.8) 622 (7.8)
 2007 699 (7.8) 65 (6.5) 634 (7.9)
 2008 747 (8.3) 81 (8.1) 666 (8.3)
 2009 914 (10.2) 89 (8.9) 825 (10.3)
 2010 812 (9.0) 94 (9.4) 718 (9.0)
 2011 835 (9.3) 94 (9.4) 741 (9.3)
 2012 891 (9.9) 113 (11.3) 778 (9.7)
 2013 872 (9.7) 102 (10.2) 770 (9.6)
 2014 834 (9.3) 95 (9.5) 739 (9.2)
 2015 846 (9.4) 92 (9.2) 754 (9.4)
 2016 864 (9.6) 110 (11.0) 754 (9.4)

*Values are the number (%).

†First thyroxine prescription before RA diagnosis. Non-autoimmune cause for thyroxine prescription not excluded.

‡Mean (± SD years).

§According to the ICD 10 registered, assessed at the time of inclusion in the SRQ.

AITD, autoimmune thyroid disease; RA, rheumatoid arthritis.